Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29004397 | 0.84 | TAAR1 (0.40) | ATMLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL22787583 | 0.77 | HTR2A (0.36) | HTR2AHTR2CATMLMNAL3MBTL1 | |
| SCHEMBL29129295 | 0.75 | HTR2A (0.43) | HTR2AHTR2CATMMEN1KMT2A | |
| SCHEMBL29988047 | 0.75 | HTR2A (0.43) | HTR2AHTR2CATMMEN1KMT2A | |
| SCHEMBL19233952 | 0.72 | TAAR1 (0.46) | HTR2AHTR2CATMALDH1A1KDM4E | |
| SCHEMBL18425277 | 0.70 | IDO1 (0.45) | HTR2ACASRALDH1A1 | |
| SCHEMBL30133794 | 0.70 | MEN1 (0.54) | LMNACASRMEN1KMT2AALDH1A1 | |
| SCHEMBL12093169 | 0.69 | ALDH1A1 (0.41) | HTR2AHTR2CATMMEN1KMT2A | |
| SCHEMBL30663885 | 0.69 | ALDH1A1 (0.41) | HTR2AHTR2CATMMEN1KMT2A | |
| SCHEMBL12719097 | 0.69 | ATM (0.36) | HTR2AHTR2CATMLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241573-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| WO-2018015879-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241573-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | PSEN1, CPT1A, IRS1 | HTR2A 3012/4885HTR2C 2972/4885ATM 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.